Cardionovum at LINC 2016

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial. Legflow was used for pre-dilatation, followed by SUPERA peripheral stent implantation versus POBA , followed by SUPERA stenting. The LEGFOW patient group demonstrates significantly superior patient results after treating extraordinarily complex TASC – C lesions of Real Life patients. Lesion length > 15cm, occlusion rate > 75%, followed by SUPERA peripheral stenting. The study aim showed the power of Legflow to significantly optimize peripheral stenting results.

Detailed information available at Cardionovum GmbH.